4D Molecular Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview

4D Molecular Therapeutics

05/08/2024 13:59

* 4D Molecular Therapeutics Inc  FDMT.OQ   FDMT.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 7 (estimated) for the period ending June 30 2024
    * The Emeryville California-based  company is expected to
report a
448.6% increase in revenue to $1.311 million from $239 thousand
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for 4D Molecular
Therapeutics Inc
is for a loss of 70 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for 4D
Molecular
Therapeutics Inc is $43.00​, above​ its last closing price
of $16.09. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.75       -0.74      -0.66     Beat    10.4
 Jan. 1 2024   -0.73       -0.74      -0.75     Missed  -1.2
 Sep. 30 2023  -0.66       -0.59      -0.24     Beat    59.6​
 Jun. 30 2023  -0.80       -0.81      -0.77     Beat    4.7
 ​​Mar.        -0.90       -0.89      -0.88     Beat    1.6
 31 2023                                                
 Jan. 1 0001   -0.83       -0.79      -0.84     Missed  -6.9​
 Sep. 30 2022  -0.88       -0.91      -0.79     Beat    13.4
 Jan. 1 0001   -0.87       -0.85      -0.87     Missed  -2.4
 This summary was machine generated August 5 at 12:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)